Replimune Group (REPL)
(Delayed Data from NSDQ)
$11.06 USD
+0.25 (2.31%)
Updated Jul 16, 2024 03:59 PM ET
After-Market: $11.06 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth F Momentum F VGM
Brokerage Reports
Replimune Group, Inc. [REPL]
Reports for Purchase
Showing records 161 - 180 ( 196 total )
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Q219 Not All Viruses Are Bad. Reiterate Buy And Raise PT To $30/Share.
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
RP1 Opdivo Update at SITC is Encouraging, in Our View; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
RP1 Ph 1 Dataset Impressive; Melanoma Program Expanded; Raising PT to $30
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
SITC - Early Data Infectious as Some Tumors Melt
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology - SITC 2019 Abstract Title Preview for Covered Companies
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
RP2 Phase 1/2 Trial Initiates Enrollment; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Positive Early Data in CSCC; Ph 2 Study Initiates
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Initial CSCC data hint that RP1 may be more potent than T-VEC.- Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
RP1''s Addition to Anti-PD-1 mAbs For Anticancer Therapy Is Justified
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
SITC Is Only 33 Days Away: Abstract Titles Released
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology - ESMO 2019 Roundup for Covered Companies
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Subsequent Therapy Imbalances Obviate T-VEC + Yervoy ESMO Data Extrapolations; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R